higher in females aged 20–26 years compared to females aged 14– 19 years (47.4% vs. 40.1%; p < 0.05). In contrast, seropositivity to all four HPV vaccine types was higher in the younger age group compared to the older age group (25.9% vs. 9.7%; p < 0.01), as was seropositivity to HPV 6/11/16 (32.5% vs. 13.5%; p < 0.01). When examined by race/ethnicity, seropositivity to any HPV vaccine type was highest in non-Hispanic Blacks (56.0%), followed by non-Hispanic Whites (45.3%) and Mexican Americans (33.7%) (p < 0.01), whereas seropositivity to all four HPV vaccine types was highest in non-Hispanic Whites (19.8%), followed by non-Hispanic Blacks (12.4%) and Mexican Americans (10.9%) (p < 0.05). There was no statistically significant difference by race/ethnicity for seropositivity to HPV 6/11/16.